PTC Therapeutics
PTCT
56.42
-1.91
-3.27%
PTC Therapeutics
US · PTCT
#2071 by market cap
Listed 1970
56.42
-1.91
-3.27%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
Quant vs Street three independent views, side by side
StockVane factor grade
D+
Momentum strategy signal
Sell
Analyst consensus
Buy
Mostly aligned, one view stands apart.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
✦ Quant Analyst Revision Trend how this is computed
Mixed
3 3
■ Upgrades■ Downgrades
- 3 upgrades vs 3 downgrades among tracked analyst rating changes.
- Most recent: Truist Financial moved from Buy to Hold on 2026-10-16.
Analyst consensus 12 analysts
Buy
Avg price target 100.00 +77.2%
Price target rangecurrent 56.42
Low62.00
Avg100.00
High137.00
Buy 83%
Hold 17%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-11-05 | J.P. Morgan | -- | Buy | 92.00 |
| 2026-11-02 | Citi | -- | Buy | 109.00 |
| 2026-11-02 | Barclays | -- | Buy | 122.00 |
| 2026-11-02 | J.P. Morgan | -- | Buy | 92.00 |
| 2026-10-30 | TD Cowen | -- | Buy | 95.00 |
| 2026-10-30 | Wells Fargo | -- | Buy | 112.00 |
| 2026-10-30 | UBS | -- | Buy | 90.00 |
| 2026-10-30 | BofA Securities | -- | Buy | -- |
| 2026-10-29 | Cantor Fitzgerald | -- | Buy | 137.00 |
| 2026-10-29 | RBC Capital | -- | Hold | 77.00 |
| 2026-10-27 | RBC Capital | -- | Hold | 75.00 |
| 2026-10-20 | Raymond James | -- | Buy | 106.00 |
| 2026-10-19 | Wells Fargo | -- | Buy | 109.00 |
| 2026-10-16 | UBS | -- | Buy | 90.00 |
| 2026-10-16 | Truist Financial | -- | Hold | 62.00 |
| 2026-10-15 | UBS | -- | Buy | 90.00 |
| 2026-10-14 | UBS | -- | Buy | 90.00 |
| 2026-10-14 | J.P. Morgan | -- | Buy | -- |
| 2026-10-09 | BofA Securities | -- | Buy | -- |
| 2026-10-07 | Barclays | -- | Buy | 122.00 |
| 2026-10-07 | RBC Capital | -- | Hold | 75.00 |
| 2026-09-21 | Cantor Fitzgerald | -- | Buy | 137.00 |
| 2026-09-14 | Leerink Partners | -- | Buy | 98.00 |
| 2026-09-02 | Wells Fargo | -- | Buy | 109.00 |
| 2026-08-30 | TD Cowen | -- | Buy | 90.00 |
Price target trend monthly average, last 3 years
Recent rating changes
| Date | Firm | Change | Target |
|---|---|---|---|
| 2026-10-16 | Truist Financial | Buy → Hold | 62.00 |
| 2026-06-09 | Citi | Hold → Buy | 108.00 |
| 2026-05-27 | Jefferies | Hold → Buy | 85.00 |
| 2026-05-08 | TD Cowen | Hold → Buy | 90.00 |
| 2026-03-30 | Jefferies | Buy → Hold | 76.00 |
| 2025-12-01 | RBC Capital | Buy → Hold | 91.00 |
Earnings history price reaction on the day
| Period | Report date | Session | Options expected | Actual move |
|---|---|---|---|---|
| 2026/Q3 | 2026-10-29 | After close | ±14.05% | -6.97% (in line) |
| 2026/Q2 | 2026-07-30 | After close | ±10.56% | -9.94% (in line) |
| 2026/Q1 | 2026-05-07 | After close | ±9.33% | +14.27% (beat) |
| 2025/Q4 | 2026-02-19 | After close | ±8.61% | +1.09% (in line) |
| 2025/Q3 | 2025-11-04 | After close | ±11.26% | +5.98% (in line) |
| 2025/Q2 | 2025-08-07 | After close | ±11.28% | -9.89% (in line) |
| 2025/Q1 | 2025-05-06 | After close | ±12.41% | +12.63% (beat) |
| 2024/Q4 | 2025-02-27 | After close | ±20.21% | +9.27% (in line) |
| 2024/Q3 | 2024-11-07 | After close | ±9.43% | +3.07% (in line) |
| 2024/Q2 | 2024-08-08 | After close | ±13.77% | -3.57% (in line) |
| 2024/Q1 | 2024-04-25 | After close | ±20.29% | +12.08% (in line) |
| 2023/Q4 | 2024-02-29 | After close | ±18.20% | +13.34% (in line) |
"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.
Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.
PTC Therapeutics discussion 0 comments